Zenas Biopharma: 56% Efficacy in Phase 3 Study INDIGO Was Not Enough - CEO Takes Advantage of [Sell-off] for a $1.6 Million Investment

Zenas BioPharma (ZBIO) is developing novel autoimmune therapies. Its core product is Obexelimab, a bifunctional antibody that inhibits B cells rather than destroying them (non-cytolytic approach). This mechanism is expected to provide high efficacy while simultaneously reducing the risk of infections. The focus is on IgG4-associated disease (IgG4-RD), multiple sclerosis (MS), and lupus (SLE). A significant competitive advantage is the possibility of subcutaneous self-injection by the patient. In early January 2026, the stock lost about 50%...